1 / 31

Clinical Trials

Clinical Trials. The Way We Make Progress Against Disease. What Are Clinical Trials?. Research studies involving people Try to answer scientific questions and find better ways to prevent, diagnose, or treat disease. Why Is Participation in Clinical Trials Important?.

chaim
Télécharger la présentation

Clinical Trials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Clinical Trials The Way We Make Progress Against Disease

  2. What Are Clinical Trials? • Research studies involving people • Try to answer scientific questions and find better ways to prevent, diagnose, or treat disease

  3. Why Is Participation in Clinical Trials Important? • The more people take part, the faster we can: - Answer critical research questions - Find better treatments and ways to prevent disease

  4. Do Many People Take Part in Clinical Trials? • Few people participate

  5. What Are Different Types of Clinical Trials? • Prevention • Treatment • Tumor or normal tissue studies • Early detection/screening • Diagnostic • Quality of life/supportive care

  6. Prevention Trials • Evaluate the effectiveness of ways to reduce the risk of a particular disease • Enroll healthy people at high risk for developing that disease

  7. Treatment Trials • What new treatments can help people with a particular disease? • What is the most effective treatment for people with that disease?

  8. Clinical Trial Phases Phase 1 trials • How does the agent affect the human body? • What dosage is safe? • What is the best dose to use for phase 2 trials?

  9. Clinical Trial Phases Phase 2 trials • Does the agent or intervention have an effect on a specific disease? • The majority of trials in neuroendocrine cancers are phase II trials

  10. Clinical Trial Phases Phase 3 trials • Is the new agent or intervention (or new use of a treatment) better than the standard? • Require large numbers of patients to answer questions

  11. Randomized Phase III Trials Participants have an equal chance to be assigned to one of two or more groups: • One gets the most widely accepted treatment (standard treatment) • The other gets the new treatment being tested, which researchers hope and have reason to believe will be better than the standard treatment

  12. Randomization

  13. Why is Randomization Important? • So all groups are as alike as possible (Even when unintended, selection bias is a major limitation to non-randomized studies.) • Provides the best way to prove the effectiveness of a new agent or intervention

  14. Clinical Trial Protocol • A recipe or blueprint • Strict scientific guidelines: --Purpose of study --How many people will participate --Who is eligible to participate --How the study will be carried out --What information will be gathered about participants --Endpoints

  15. Benefits of Participation Possible benefits: • Patients will receive, at a minimum, the best standard treatment (if one exists) • If the new treatment or intervention is proven to work, patients may be among the first to benefit • Patients have a chance to help others and improve patient care

  16. Risks of Participation Possible risks: • New treatments or interventions under study are not always better than, or even as good as, standard care • Even if a new treatment has benefits, it may not work for every patient

  17. Patient Protection • Federal regulations ensure that people are told about the benefits, risks, and purpose of research before they agree to participate

  18. How Are Patients’ Rights Protected? • Informed consent • Scientific review • Institutional review boards (IRBs) • Data safety and monitoring boards (DSMBs)

  19. How Are Patients’ Rights Protected? Informed Consent: • Purpose • Procedures • Potential risks and benefits • Individual rights

  20. How Are Patients’ Rights Protected? • Scientific review (NCI designated Cancer Centers require this for all trials) • Institutional review boards (IRBs) are required by federal law for trials that are: --Federally funded --Subject to FDA regulation

  21. How Are Patients’ Rights Protected? Data and safety monitoring boards: • Ensure that risks are minimized • Ensure data integrity • Stop a trial if safety concerns arise or objectives have been met

  22. Why Do So Few People Participate in Clinical Trials? Sometimes patients: • Don’t know about clinical trials • Don’t have access to clinical trials • May be afraid or suspicious of research • Can’t afford to participate • May not want to go against health care provider’s wishes

  23. Why Do So Few People Participate in Clinical Trials? Health care providers might: • Lack awareness of appropriate clinical trials • Be unwilling to “lose control” of a person’s care • Believe that standard therapy is best • Be concerned that clinical trials add administrative burdens

  24. DFHCC Clinical Trials in Neuroendocrine Tumors • Therapeutic: • A multicenter, randomized, blinded efficacy and safety study of pasireotide LAR vs octreotide LAR in patients with metastatic carcinoid tumors whose disease-related symptoms are inadequately controlled by somatostatin analogues. • Phase III Prospective Randomized Comparison of Depot Octreotide plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC#704865) in Advanced, Poor Prognosis Carcinoid • Patients Non-Therapeutic: • Sample Collection in Patients with Neuroendocrine • Protein Expression in Carcinoid Tumors

  25. DFHCC Clinical Trials in Neuroendocrine Tumors • Therapeutic: (Pending) • Ph II AMG479 in Carcinoid and Panc Neuroendocrine • Octreotide Implant in Carcinoid • LX 1006 in Carcinoid pts. Refractory to Octreotide

  26. Your health care provider National Library of Medicine www.ClinicalTrials.gov Where to Find Additional Clinical Trial Information :

  27. Neuroendocrine Cancers • The important role of a multimodality approach to the disease from time of diagnosis but continuing throughout the course of the patient’s care, including: • Surgeons for resections of primary lesions and where appropriate, metastatic disease • Interventional and/or Vascular radiologists for directed therapies (such as RFA or chemoembolization) especially for liver lesions • Medical oncologists for systemic therapy, including LAR octreotide treatment as well as various chemotherapeutic agents as appropriate • Radiation oncologists for treatment of appropriate disease such as painful bony lesions.

  28. Neuroendocrine Tumors (conclusion continued) • The variable natural history of these tumors. • Some individuals, such as this patient, have a relatively indolent history, doing quite well despite metastatic disease • Others have a more aggressive course requiring ongoing chemotherapy or chemoembolization to control their disease and symptoms

  29. Neuroendocrine Tumors (conclusion continued) • Thus, this is a disease where it is very important that each patient be evaluated carefully by the different disciplines and has disease tailored appropriately.

More Related